GLP-1 and type 2 diabetes: physiology and new clinical advances.

@article{Combettes2006GLP1AT,
  title={GLP-1 and type 2 diabetes: physiology and new clinical advances.},
  author={Murielle M J Combettes},
  journal={Current opinion in pharmacology},
  year={2006},
  volume={6 6},
  pages={598-605}
}
The first antidiabetic treatment (exenatide; Byetta) based on the incretin hormone glucagon-like peptide-1 (GLP-1) was approved in 2005 as an adjunctive therapy in diabetic patients in whom sulfonylurea, metformin or both had failed. Many GLP-1 mimetics or dipeptidyl peptidase IV inhibitors are currently in clinical development for the treatment of type 2 diabetes and show promising results in the improvement of glucose homeostasis. Furthermore, the ability of GLP-1 to enhance pancreatic beta… CONTINUE READING
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…